Pentoxifylline does not prevent the cytokine-induced first dose reaction following OKT3 - A randomized, double-blind placebo-controlled study

Transplantation

Volumn 61, Issue 4, 1996, Pages 573-577

  Vincenti, Flavio ^a   Danovitch, Gabriel M ^b   Neylan, John F ^b   Steiner, Robert W ^b   Everson, Michael P ^b   Gaston, Robert S ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; DIPHENHYDRAMINE; METHYLPREDNISOLONE; OKT 3; PARACETAMOL; PENTOXIFYLLINE; PLACEBO;

ARTICLE; CHILL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SCREENING; DYSPNEA; FEMALE; FEVER; GASTROINTESTINAL SYMPTOM; GRAFT REJECTION; HEADACHE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY ALLOGRAFT; MALE; NEUROLOGIC DISEASE; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL;

ADULT; ANIMALS; ANTIGENS, CD3; CYTOKINES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERFERON TYPE II; KIDNEY; KIDNEY TRANSPLANTATION; LYMPHOCYTE COUNT; LYMPHOCYTES; MALE; MICE; MIDDLE AGED; MUROMONAB-CD3; PENTOXIFYLLINE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0029913758     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199602270-00010     Document Type: Article

References (25)

1. Ortho Multicenter Transplant Study Group. A randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants. N Eng J Med 1985; 313: 337.
2. Debure A, Chkoff N, Chatenoud L, et al. One-month prophylactic use of OKT3 in cadaver kidney transplant recipients. Transplantation 1988; 45: 546.
3. Jeyarajah DR, Thistlethwaite JR. General aspects of cytokine-release syndrome: timing and incidence of symptoms. Transplant Proc 1993; 25(suppl 1): 16.
4. Gaston RS, Heierhoi MH, Patterson T, et al. OKT3 first dose reaction: association with T cell subsets and cytokine release. Kidney Int 1991; 39: 141.
5. Abramowicz D, Schandene L, Goldman M, et al. Release of tumor necrosis factor, interleukin 2, and gamma-interferon in serum after injection of OKT3 monoclonal antibody in kidney transplant recipients. Transplantation 1989; 47: 606.
6. Ferran C, Sheehan K, Dy M, et al. Cytokine-related syndrome following injection of anti-CD3 monoclonal antibody: further evidence for transient in vivo T cell activation. Eur J Immunol 1990; 20: 509.
7. Chatenoud L, Ferran C, Legendre C, et al. In vivo cell activation following OKT3 administration. Transplantation 1990; 49: 697.
8. Han J, Thompson P, Beutler B. Dexamethasone and pentoxifylline inhibit endotoxin-induced cachectin/tumor necrosis factor synthesis at separate points in the signaling pathway. J Exp Med 1990; 172: 391.
9. Strieter RM, Remick DG, Ward PA, Spengler RN, Lynch JP, Larrick J. Cellular and molecular regulation of tumor necrosis factor-alpha production by pentoxifylline. Biochem Biophys Res Commun 1988; 155: 1230.
10. Zabel P, Schönharting MM, Wolter DT, Schade UF. Oxpentifylline in endotoxaemia. Lancet 1989; 2: 1474.
11. Schönharting MM, Schade UF. The effect of pentoxifylline in septic shock-new pharmacological aspects of an established drug. J Med 1989; 20: 97.
12. Noel P, Nelson S, Bokulic R, et al. Pentoxifylline inhibits lipopolysaccharide-induced serum tumor necrosis factor and mortality. Life Sci 1990; 47: 1023.
13. Vincenti FG, Vasconcelos M, Birnbaum JL. Pentoxifylline reduces the first-dose reactions following OKT3. Transplantation Proc 1993; 25(suppl 1): 57.
14. Zabel P, Leimenstoll G, Schröder R, Elfeldt R, Schlauk M, Niedermayer W. Pentoxifylline suppresses OKT3-induced tumor necrosis factor alpha formation in renal transplant recipients. Z Transplant Med 1991; 3: 65.
15. Schroeder T, First R, Weiskittel P, et al. Indomethacin and pentoxifylline as premedication for OKT3 related first dose reactions. Presented at the 26th Annual Meeting of the American Society of Nephrology, Boston, MA, 1993.
16. Russell JD, Ludwin D, Carlisle EJ, Holland MD, Gauldie J, Lazarovits AI. Prevention of OKT3 induced symptoms by blockade of TNF α with pentoxifylline. Presented at the 12th annual meeting of the American Society of Transplant Physicians, Houston, TX, 1993.
17. DeVault GA, Kohan DE, Nelson EW, et al. The effects of oral pentoxifylline on the cytokine release syndrome during inductive OKT3. Transplantation 1994; 57: 532.
18. Alegre M-L, Gastaldello K, Abramowicz D, et al. Evidence that pentoxifylline reduces anti-CD3 monoclonal antibody-induced cytokine release syndrome. Transplantation 1991; 52: 674.
19. Martich GL, Danner RL, Ceska M, Suffredini AF. Detection of interleukin 8 and tumor necrosis factor in normal humans after intravenous endotoxin: the effect of antiinflammatory agents. J Exp Med 1991; 178: 1021.
20. Chatenoud L, Legendre C, Ferran C, Bach J-F, Kreis H. Corticosteroid inhibition of the OKT3-induced cytokine-related syndrome - dosage and kinetics prerequisites. Transplantation 1991; 51: 334.
21. Shield CF, Kahana L, Pirsch J, et al. Use of Indomethacin to minimize the adverse reactions associated with orthoclone OKT3 treatment of kidney allograft rejection. Transplantation 1992; 54: 164.
22. Charpentier B, Hiesse C, Lantz O, et al. Evidence that antihuman tumor necrosis factor monoclonal antibody prevents OKT3-induced acute syndrome. Transplantation 1992; 54: 997.
23. Ishizaka A, Wu Z, Stephens KE, et al. Attenuation of acute lung injury in septic guinea pigs by pentoxifylline. Am Rev Respir Dis 1988; 136: 376.
24. Bianco JA, Appelbaum FR, Nemunaitis J, et al. Phase I-II trial of pentoxifylline for the prevention of transplant-related toxicities following bone marrow transplantation. Blood 1991; 78: 1205.
25. Leimenstoll G, Zabel P, Schroeder P, et al. Suppression of OKT3-induced tumor necrosis factor alpha formation by pentoxifylline in renal transplant recipients. Transplantation Proc 1993; 25: 561.